ArticleInternal and emergency medicine2019

Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease.

Cosmo Godino et al.PubMed ↗Publisher ↗

No numbers read from the abstract.